# Apellis Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apellis-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Waltham, US
- Website: www.apellis.com
- Total disclosed funding: $147M
- Latest round: Series E (Aug 7, 2017)
- Investors on record: 16

## About

Apellis Pharmaceuticals develops innovative therapies targeting complement-mediated diseases, focusing on serious medical conditions with the goal of improving patient outcomes through advanced treatment solutions.Founded in 2009, Apellis Pharmaceuticals, Inc. is based in Waltham, US. The company specializes in creating therapies for complement-mediated diseases. Cedric Francois, one of the co-founders, leads as CEO. In November 2021, Apellis raised USD 350 mn in a Private Placement, bringing its total funding to USD 350 mn through multiple rounds of investment.Apellis Pharmaceuticals specializes in innovative therapies for complement-mediated diseases, with APL-2 being its flagship complement inhibitor. This product is designed to treat geographic atrophy, a progressive retinal disease. The company primarily markets its products in the United States, with plans for international expansion to increase patient access to its therapeutic options.In the most recent year of 2023, Apellis Pharmaceuticals reported revenue of USD 396.59 mn, with an EBITDA of USD -515.12 mn. Revenue is generated through the sale of its therapeutics, including APL-2, utilizing a distribution model that encompasses direct transactions and collaborations with healthcare providers and specialty pharmacies.Apellis Pharmaceuticals plans to utilize recent funding from a USD 350 mn Private Placement in February 2023 to launch Phase 3 trials for APL-2 in paroxysmal nocturnal hemoglobinuria and to accelerate development for other indications. The company's strategy also includes expanding into new international markets to enhance patient access to its innovative therapies.

## Funding rounds

- Series E, Aug 7, 2017, $60M — Sofinnova Investments, Vivo Capital, F-Prime Capital, 5Y Capital, Clough Capital, Epidarex Capital, Sectoral Asset Management, VenBio, Cormorant Asset Management
- Series D, Feb 8, 2016, $47M — AJU IB Investment, 5Y Capital, Epidarex Capital, Hillhouse Investment, VenBio, Cormorant Asset Management
- Series C, Dec 5, 2014, $33M — AJU IB Investment, 5Y Capital, Epidarex Capital
- Series C, Jul 30, 2013, $6M — Pegasus Capital Advisors, Morningside
- Series B, Jun 20, 2011, $1.3M — HealthCare Ventures, Pegasus Capital Advisors, Kentucky Science and Technology Corporation, Masa Life Science

## Investors

- HealthCare Ventures — Series B
- Pegasus Capital Advisors (https://capitalatlas.ai/funds/pegasus-capital-advisors) — Series B, Series C
- Kentucky Science and Technology Corporation — Series B
- Masa Life Science — Series B
- Morningside (https://capitalatlas.ai/funds/morningside) — Series C
- AJU IB Investment (https://capitalatlas.ai/funds/aju-ib-investment) — Series C, Series D
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series C, Series D, Series E
- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series C, Series D, Series E
- Hillhouse Investment (https://capitalatlas.ai/funds/hillhouse-investment) — Series D
- VenBio (https://capitalatlas.ai/funds/venbio) — Series D, Series E
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D, Series E
- Sofinnova Investments (https://capitalatlas.ai/funds/sofinnova-investments) — Series E
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series E
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series E
- Clough Capital — Series E
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series E